Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer
Alba Navarro-Ocón,
Jose L. Blaya-Cánovas,
Araceli López-Tejada,
Isabel Blancas,
Rosario M. Sánchez-Martín,
María J. Garrido,
Carmen Griñán-Lisón,
Jesús Calahorra,
Francisca E. Cara,
Francisco Ruiz-Cabello,
Juan A. Marchal,
Natalia Aptsiauri,
Sergio Granados-Principal
Affiliations
Alba Navarro-Ocón
GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
Jose L. Blaya-Cánovas
GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
Araceli López-Tejada
GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
Isabel Blancas
Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
Rosario M. Sánchez-Martín
GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
María J. Garrido
Department of Pharmaceutical Technology and Chemistry, School of Pharmacy & Nutrition, Navarra Institute for Health Research (IdisNA), University of Navarra, 31080 Pamplona, Spain
Carmen Griñán-Lisón
GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
Jesús Calahorra
GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
Francisca E. Cara
GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
Francisco Ruiz-Cabello
Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
Juan A. Marchal
Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
Natalia Aptsiauri
Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain
Sergio Granados-Principal
GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain
Breast cancer is the most common type of malignancy and leading cause of cancer death among women worldwide. Despite the current revolutionary advances in the field of cancer immunotherapy, clinical response in breast cancer is frequently below expectations, in part due to various mechanisms of cancer immune escape that produce tumor variants that are resistant to treatment. Thus, a further understanding of the molecular events underlying immune evasion in breast cancer may guarantee a significant improvement in the clinical success of immunotherapy. Furthermore, nanomedicine provides a promising opportunity to enhance the efficacy of cancer immunotherapy by improving the delivery, retention and release of immunostimulatory agents in targeted cells and tumor tissues. Hence, it can be used to overcome tumor immune escape and increase tumor rejection in numerous malignancies, including breast cancer. In this review, we summarize the current status and emerging trends in nanomedicine-based strategies targeting cancer immune evasion and modulating the immunosuppressive tumor microenvironment, including the inhibition of immunosuppressive cells in the tumor area, the activation of dendritic cells and the stimulation of the specific antitumor T-cell response.